Evidence map›Paper›PMID 30192823›Full record

ArticlePloS one2018

Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes.

Barbara K Marebwa, Robert J Adams, Gayenell S Magwood, Mark Kindy, Janina Wilmskoetter, Myles Wolf, Leonardo Bonilha

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Collagen type IV as the link between arterial stiffness and dementia.American journal of translational research · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Regulatory Roles of Bone in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2020
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Barbara K MarebwaDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.ORCID 0000-0002-5664-0408
Robert J AdamsDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.
Gayenell S MagwoodDepartment of Nursing, Medical University of South Carolina, Charleston, SC, United States of America.
Mark KindyDepartment of Pharmaceutical Sciences, University of South Florida, Tampa, FL, United States of America.
Janina WilmskoetterDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.
Myles WolfDepartment of Medicine, Duke University School of Medicine, Durham, NC, United States of America.
Leonardo BonilhaDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.
Medical University of South Carolina · USDuke University · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated levels of FGF23 in individuals with chronic kidney disease (CKD) are associated with adverse health outcomes, such as increased mortality, large vessel disease, and reduced white matter volume, cardiovascular and cerebrovascular events. Apart from the well-known link between cardiovascular (CV) risk factors, especially diabetes and hypertension, and cerebrovascular damage, elevated FGF23 is also postulated to be associated with cerebrovascular damage independently of CKD. Elevated FGF23 predisposes to vascular calcification and is associated with vascular stiffness and endothelial dysfunction in the general population with normal renal function. These factors may lead to microangiopathic changes in the brain, cumulative ischemia, and eventually to the loss of white matter fibers. The relationship between FGF23 and brain integrity in individuals without CKD has hitherto not been investigated. In this study, we aimed to determine the association between FGF23, and white matter integrity in a cohort of 50 participants with varying degrees of CV risk burden, using high resolution structural human brain connectomes constructed from MRI diffusion images. We observed that increased FGF23 was associated with axonal loss in the frontal lobe, leading to a fragmentation of white matter network organization. This study provides the first description of the relationship between elevated levels of FGF23, white matter integrity, and brain health. We suggest a synergistic interaction of CV risk factors and FGF23 as a potentially novel determinant of brain health.

Indexed as

Neural Networks, ComputerAxonsCardiovascular DiseasesCohort StudiesEndothelium, VascularFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFrontal LobeHumansMagnetic Resonance ImagingMaleMiddle AgedRenal Insufficiency, ChronicRisk FactorsVascular CalcificationFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factors

Identifiers

PMID30192823
PMCPMC6128563
OpenAlexW2891654939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.